Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation. Human antibodies such as PG9 nonetheless engage V1/V2 and neutralize 80% of HIV-1 isolates. Here we report the structure of V1/V2 in complex with PG9. V1/V2 forms a four-stranded β-sheet domain, in which sequence diversity and glycosylation are largely segregated to strand-connecting loops. PG9 recognition involves electrostatic, sequence-independent and glycan interactions: the latter account for over half the interactive surface but are of sufficiently weak affinity to avoid autoreactivity. The structures of V1/V2-directed antibodies CH04 and PGT145 indicate that they share a common mode of glycan penetration by extended anionic loops. In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [507]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · cited 1×
“and a molecular replacement solution for the 1FD6-ZM109 data set consisting of two unbound PG9 Fab molecules per asymmetric unit was obtained using PHASE”
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Nicholls, A., Sharp, K. A., & Honig, B. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340110407 · Cited by 5,240
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,896
The Anatomy and Taxonomy of Protein Structure
Richardson, J. S. (1981) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60520-3 · Cited by 3,375
Research works printed but not linked: 2
- Zolla-Pazner S V2-reactive antibodies in RV144 vaccinees’ plasma AIDS Res Hum Retroviruses 27 A-21 2011
- Otwinowski, Z. & Minor, W. in Methods Enzymol. Vol. 276, 307–326 (Academic Press, 1997)
Cited by
Items 201–300 of 831
Computational tools for epitope vaccine design and evaluation
He, L., & Zhu, J. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.013 · Cited by 81
“As shown by recent studies, N -linked glycans are major structural elements of several HIV-1 epitopes recognized by bnAbs [8,12,14–16].”
ResultSelf-citationAlam, S. M., Dennison, S. M., Aussedat, B., Vohra, Y., Park, P. K., Fernández‐Tejada, A., Stewart, S. M., Jaeger, F. H., Anasti, K. M., Blinn, J. H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317855110 · Cited by 74
“Furthermore, the requirement of the adoption of β-strand conformation of the V1V2 glycopeptides for PG9 binding is consistent with the reported structure of PG9 binding to scaffolded V1V2 (17).”
BackgroundMethodSelf-citationDevelopment of prophylactic vaccines against HIV-1
Schiffner, T., Sattentau, Q. J., & Dorrell, L. (2013) · Retrovirology · doi:10.1186/1742-4690-10-72 · Cited by 84
“These bNmAbs bind epitopes in the V1V2 loop (PG9) and V3 loop base (PGT128), and require an unusually long CDR3 loop to access the peptide ‘floor’ of the canyon whilst also contacting the glycan ‘walls’ [102].”
BackgroundInfluentialRecent advances on smart glycoconjugate vaccines in infections and cancer
Anderluh, M., Berti, F., Bzducha‐Wróbel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik-Popińska, K., Ferhati, X., Holmdahl, R., Jovanović, D. J., et al. (2021) · FEBS Journal · doi:10.1111/febs.15909 · Cited by 76
Kong, L., de la Peña, A. T., Deller, M. C., Garcés, F., Sliepen, K., Hua, Y., Stanfield, R. L., Sanders, R. W., & Wilson, I. A. (2015) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004715013917 · Cited by 81
“…the discovery and isolation of exceptionally potent, broadly neutralizing antibodies (bNAbs; Walker et al., 2009, 2011; Scheid et al., 2011), some of whose epitopes overlap on several key supersites of vulnerability (Kong et al., 2013; Zhou et al., 2010; McLellan et al., 2011; Scharf et al., 2014).”
BackgroundSelf-citationElectrochemical lectin based biosensors as a label-free tool in glycomics
Bertók, T., Katrlík, J., Gemeiner, P., & Tkáč, J. (2012) · Microchimica Acta · doi:10.1007/s00604-012-0876-4 · Cited by 77
Panico, M., Bouché, L., Binet, D., O’Connor, M.-J., Rahman, D., Pang, P., Canis, K., North, S. J., Desrosiers, R. C., Chertova, E. N., et al. (2016) · Scientific Reports · doi:10.1038/srep32956 · Cited by 85
Tuberculosis vaccine development: strength lies in tenacity
Kaufmann, S. H. E. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.03.004 · Cited by 86
McGuire, A. T., Glenn, J. A., Lippy, A., & Stamatatos, L. (2013) · Journal of Virology · doi:10.1128/jvi.03228-13 · Cited by 83
bNAber: database of broadly neutralizing HIV antibodies
Eroshkin, A. M., LeBlanc, A., Weekes, D., Post, K. W., Li, Z., Rajput, A., Butera, S., Burton, D. R., & Godzik, A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1083 · Cited by 71
Self-citationPhenotypic Correlates of HIV-1 Macrophage Tropism
Arrildt, K. T., LaBranche, C. C., Joseph, S., Dukhovlinova, E., Graham, W. D., Ping, L., Schnell, G., Sturdevant, C. B., Kincer, L. P., Mallewa, M., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00946-15 · Cited by 85
“4c), suggesting that M-tropic viruses may differ in the Env protein conformation of the V1/V2 region, which is now understood to be highly ordered (52, 98) and is thought to contribute to the structure and function of the Env trimer (99–103).”
BackgroundZolla‐Pazner, S., Cohen, S. S., Boyd, D. F., Kong, X., Seaman, M. S., Nussenzweig, M. C., Klein, F., Overbaugh, J. M., & Totrov, M. M. (2015) · Journal of Virology · doi:10.1128/jvi.01645-15 · Cited by 73
“The bridging sheet is an antiparallel sheet in the monomer but assumes a mixed parallel/antiparallel conformation in the SOSIP trimer (63).”
BackgroundTargeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability
Mason, R. D., Welles, H. C., Adams, C., Chakrabarti, B. K., Gorman, J., Zhou, T., Nguyen, R., O'Dell, S. J., Lusvarghi, S., Bewley, C. A., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005537 · Cited by 69
Self-citationHIV antibodies for treatment of HIV infection
Margolis, D. M., Koup, R. A., & Ferrari, G. (2017) · Immunological Reviews · doi:10.1111/imr.12506 · Cited by 75
Cobb, D. A., Smith, N. S., Edagwa, B., & McMillan, J. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1783233 · Cited by 87
The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel
Pan, R., Górny, M. K., Zolla‐Pazner, S., & Kong, X. (2015) · Journal of Virology · doi:10.1128/jvi.00754-15 · Cited by 71
“disulfide bond and glycans of V1V2 (11).”
BackgroundMethodInfluentialResidue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains
Chuang, G., Acharya, P., Schmidt, S. D., Yang, Y., Louder, M. K., Zhou, T., Kwon, Y. D., Pancera, M., Bailer, R. T., Doria‐Rose, N. A., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00984-13 · Cited by 71
“Some of the neutralization data have been previously published (4, 25, 30, 33, 36, 43, 44).”
BackgroundSelf-citationBouvin-Pley, M., Morgand, M., Moreau, A., Jestin, P., Simonnet, C., Tran, L., Goujard, C., Meyer, L., Barin, F., & Braibant, M. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003477 · Cited by 81
Voss, J. E., Andrabi, R., McCoy, L. E., de Val, N., Fuller, R. P., Messmer, T., Su, C.-Y., Sok, D., Khan, S. N., Garcés, F., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.024 · Cited by 69
“d Precursor V2-apex bnAb neutralization-sensitive Envs possess a common glycan hole d Sensitive Envs can be adapted to SOSIP format as V2-apex- focusing immunogens d Immunogens elicit nAbs targeting critical components of the bnAb epitope in rabbits d Select nAbs elicited show dependence on V2 lysines and glycans also…”
BackgroundInfluentialSelf-citationKwon, Y. D., Chuang, G., Zhang, B., Bailer, R. T., Doria‐Rose, N. A., Gindin, T. S., Lin, B. C., Louder, M. K., McKee, K., O'Dell, S. J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.023 · Cited by 70
“We also chose Arg, which can improve solubility, can mediate interactions with phospholipid membranes, or can interfere with antigen interactions through steric clashes (Gorman et al., 2016; McLellan et al., 2011; Robison et al., 2016; Trevino et al., 2007).”
BackgroundSelf-citationMurin, C. D., Julien, J., Sok, D., Stanfield, R. L., Khayat, R., Cupo, A., Moore, J. P., Burton, D. R., Wilson, I. A., & Ward, A. B. (2014) · Journal of Virology · doi:10.1128/jvi.01229-14 · Cited by 74
Self-citationHIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
Bonsignori, M., Alam, S. M., Liao, H., Verkoczy, L. K., Tomaras, G. D., Haynes, B. F., & Moody, M. A. (2012) · Trends in Microbiology · doi:10.1016/j.tim.2012.08.011 · Cited by 73
“Interestingly, these groups of bnAbs neutralize viruses with different patterns of breadth and potency, display different degrees of sensitivity to amino acid substitution, and different orientations of the HCDR3 loop in complex with the V1/V2 domain [21, 63].”
BackgroundSelf-citationSingh, K., Burkhardt, M., Nakuchima, S., Herrera, R., Muratova, O. V., Gittis, A. G., Kelnhofer, E., Reiter, K., Smelkinson, M. G., Veltri, D., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01123-9 · Cited by 73
Self-citationMelzi, E., Willis, J. R., Ma, K. M., Lin, Y., Kratochvil, S., Berndsen, Z. T., Landais, E., Kalyuzhniy, O., Nair, U., Warner, J. E., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.003 · Cited by 66
“PCT64 precursor responses to GT2 are driven by the heavy chain In Apex-directed bnAbs, the HCDR3 is a major binding determinant (Pancera et al., 2010; Pejchal et al., 2010; McLellan et al., 2011; Julien et al., 2013; Andrabi et al., 2015).”
Self-citationHoffenberg, S., Powell, R., Carpov, A., Wagner, D., Wilson, A. J., Pond, S. L. K., Lindsay, R. W. B., Arendt, H. E., DeStefano, J., Phogat, S. K., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02827-12 · Cited by 74
“From the crystal structure of PG9 with variable regions 1 and 2 as well as mutation analyses, glycosylation at position N160 as well as at position N156 is required for binding to PG9 (20, 25).”
BackgroundSelf-citationMultiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies
Moore, P. L., Sheward, D. J., Nonyane, M., Ranchobe, N., Hermanus, T., Gray, E. S., Karim, S. S. A., Williamson, C. E., & Morris, L. (2013) · Journal of Virology · doi:10.1128/jvi.03424-12 · Cited by 72
“We have previously described CAP256, a subtype C superinfected individual who developed potent BCN antibodies targeting a quaternary neutralizing epitope involving the V2 region (31), similar to the PG9 and PG16 MAbs (15).”
BackgroundInfluentialHow HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design
Pancera, M., Changela, A., & Kwong, P. D. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000360 · Cited by 70
Self-citationThe HIV-1 transmission bottleneck
Kariuki, S. M., Selhorst, P., Ariën, K. K., & Dorfman, J. R. (2017) · Retrovirology · doi:10.1186/s12977-017-0343-8 · Cited by 93
Guttman, M., Kahn, M., Garcia, N. K., Hu, S.-L., & Lee, K. K. (2012) · Journal of Virology · doi:10.1128/jvi.07224-11 · Cited by 83
“The density alongside CD4 in the SAXS envelope also accommodates the recently reported V1/V2 structure (39) (Fig.”
BackgroundMethodInfluentialBasic research in HIV vaccinology is hampered by reductionist thinking
Regenmortel, M. H. V. V. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00194 · Cited by 67
Yates, N. L., deCamp, A. C., Korber, B., Liao, H., Irene, C., Pinter, A., Peacock, J., Harris, L. J., Sawant, S. S., Hraber, P., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01843-17 · Cited by 64
Self-citationThe structure of an infectious immature flavivirus redefines viral architecture and maturation
Newton, N. D., Hardy, J. M., Modhiran, N., Hugo, L. E., Amarilla, A. A., Bibby, S., Venugopal, H., Harrison, J. J., Traves, R., Hall, R. A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe4507 · Cited by 63
Moin, S. M., Boyington, J. C., Boyoglu-Barnum, S., Gillespie, R. A., Cerutti, G., Cheung, C. S., Cagigi, A., Gallagher, J. R., Brand, J., Prabhakaran, M. S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.015 · Cited by 64
Self-citationRantalainen, K. I., Berndsen, Z. T., Murrell, S., Cao, L., Omorodion, O., Torres, J. L., Wu, M., Umotoy, J. C., Copps, J., Poignard, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.046 · Cited by 63
Self-citationCryo-EM Structure of Full-length HIV-1 Env Bound With the Fab of Antibody PG16
Pan, J., Peng, H., Chen, B., & Harrison, S. C. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.11.028 · Cited by 61
Langley, D. R., Kimura, S. R., Sivaprakasam, P., Zhou, N., Dicker, I. B., McAuliffe, B. V., Wang, T., Kadow, J. F., Meanwell, N. A., & Krystal, M. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24726 · Cited by 60
Aussedat, B., Vohra, Y., Park, P. K., Fernández‐Tejada, A., Alam, S. M., Dennison, S. M., Jaeger, F. H., Anasti, K. M., Stewart, S. M., Blinn, J. H., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405990z · Cited by 60
Self-citationNonhuman Primate Models for HIV/AIDS Vaccine Development
Sui, Y., Gordon, S. N., Franchini, G., & Berzofsky, J. A. (2013) · Current Protocols in Immunology · doi:10.1002/0471142735.im1214s102 · Cited by 67
Journal of AIDS & Clinical Research
Kong, L., & Sattentau, Q. J. (2019) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113 · Cited by 59
Correction: Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
Hoot, S., McGuire, A. T., Cohen, K. W., Strong, R. K., Hangartner, L., Klein, F., Diskin, R., Scheid, J. F., Sather, D. N., Burton, D. R., et al. (2013) · PLoS Pathogens · doi:10.1371/annotation/ed7c0148-97eb-4416-824d-6e6d1aaeceef · Cited by 62
Self-citationModeling Immunity with Rosetta: Methods for Antibody and Antigen Design
Schoeder, C. T., Schmitz, S., Adolf‐Bryfogle, J., Sevy, A. M., Finn, J. A., Sauer, M. F., Bozhanova, N. G., Mueller, B. K., Sangha, A. K., Bonet, J., et al. (2021) · Biochemistry · doi:10.1021/acs.biochem.0c00912 · Cited by 64
Self-citationTransplanting Supersites of HIV-1 Vulnerability
Zhou, T., Zhu, J., Yang, Y., Gorman, J., Ofek, G., Srivatsan, S. R., Druz, A., Lees, C. R., Lu, G., Soto, C. S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099881 · Cited by 61
Self-citationSoluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains
Joyce, M. G., Georgiev, I. S., Yang, Y., Druz, A., Geng, H., Chuang, G., Kwon, Y. D., Pancera, M., Rawi, R., Sastry, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.016 · Cited by 62
Self-citationAnti-HIV B Cell Lines as Candidate Vaccine Biosensors
Ota, T., Doyle-Cooper, C., Cooper, A. B., Huber, M., Falkowska, E., Doores, K. J., Hangartner, L., Le, K. M., Sok, D., Jardine, J. G., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202165 · Cited by 59
Self-citationYang, W., Shah, P., Eshghi, S. T., Yang, S., Sun, S., Ao, M., Rubin, A., Jackson, J. B., & Zhang, H. (2014) · Analytical Chemistry · doi:10.1021/ac500876p · Cited by 62
Buffalo, C. Z., Bahn-Suh, A. J., Hirakis, S. P., Biswas, T., Amaro, R. E., Nizet, V., & Ghosh, P. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.155 · Cited by 56
“Broadly neutralizing antibodies (bNAbs) have been identified for several highly antigenically variable microbial pathogens, including HIV and influenza virus 30,31,32,33 .”
Antibody gene transfer with adeno‐associated viral vectors as a method for HIV prevention
Brady, J. M., Baltimore, D., & Balazs, A. B. (2017) · Immunological Reviews · doi:10.1111/imr.12478 · Cited by 57
Alternative conformations of a major antigenic site on RSV F
Jones, H. G., Battles, M. B., Lin, C.-C., Bianchi, S., Corti, D., & McLellan, J. S. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007944 · Cited by 62
Self-citationSynthetic carbohydrate antigens for HIV vaccine design
Wang, L. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.10.001 · Cited by 58
Self-citationA Mechanistic Understanding of Allosteric Immune Escape Pathways in the HIV-1 Envelope Glycoprotein
Sethi, A., Jianhui, T., Derdeyn, C. A., Korber, B., & Gnanakaran, S. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003046 · Cited by 58
Aricescu, A. R., & Owens, R. J. (2013) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2013.04.003 · Cited by 63
Progress in HIV-1 vaccine development
Haynes, B. F., & McElrath, M. J. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328361d178 · Cited by 70
Self-citationCheng, C., Pancera, M., Bossert, A., Schmidt, S. D., Chen, R. E., Chen, X., Druz, A., Narpala, S., Doria‐Rose, N. A., McDermott, A. B., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02380-15 · Cited by 58
“1A), as we have in the past (16), which does not require low-pH or high-salt elution steps that could affect trimer folding.”
BackgroundMethodSelf-citationAndrabi, R., Su, C.-Y., Liang, C. J., Shivatare, S. S., Briney, B. S., Voss, J. E., Khan, S. N., Wu, C., Wong, C., & Burton, D. R. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.006 · Cited by 59
“Further, structural studies have shown that PG9 and PG16 Abs make contact with N160 and N156 or N173 glycans on Env V2 scaffolds through both germline and somatically mutated residues (McLellan et al., 2011; Pancera et al., 2013).”
InfluentialSelf-citationBouvin-Pley, M., Morgand, M., Meyer, L., Goujard, C., Moreau, A., Mouquet, H., Nussenzweig, M. C., Pace, C. S., Ho, D. D., Björkman, P. J., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02083-14 · Cited by 57
Self-citationEnvelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection
Ferrari, G., Haynes, B. F., Koenig, S., Nordstrom, J. L., Margolis, D. M., & Tomaras, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.173 · Cited by 60
Self-citationRational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers
Aldon, Y., McKay, P. F., Allen, J. D., Ozorowski, G., Lévai, R. F., Tolazzi, M., Rogers, P., He, L., de Val, N., Fábián, K., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.051 · Cited by 54
Self-citationStanfield, R. L., & Wilson, I. A. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0012-2013 · Cited by 87
Self-citationPal, A., Ganguly, A., Wei, P., Barman, S. R., Chang, C., & Lin, Z. (2023) · Advanced Science · doi:10.1002/advs.202307266 · Cited by 53
Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection
Parsons, M. S., Lloyd, S. B., Lee, W. S., Kristensen, A. B., Amarasena, T. H., Keele, B. F., Lifson, J. D., LaBranche, C. C., Montefiori, D. C., Wines, B. D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1483 · Cited by 57
Seabright, G. E., Cottrell, C. A., van Gils, M. J., D’Addabbo, A., Harvey, D. J., Behrens, A., Allen, J. D., Watanabe, Y., Scaringi, N., Polveroni, T. M., et al. (2020) · Structure · doi:10.1016/j.str.2020.04.022 · Cited by 54
Self-citationTo bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1
Griffith, S. A., & McCoy, L. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708227 · Cited by 74
“Furthermore, bnAbs targeting the trimer apex have been shown to preferentially recognise the quaternary structure of Env (exhibiting a b-conformation of V2) (157), and thus bind intermediate and/or closed conformations of the Env trimer exhibited by tier 1B and tier 2/3 viruses, rather than open conformations characte…”
BackgroundZhang, Y.-N., Paynter, J., Antanasijevic, A., Allen, J. D., Eldad, M., Lee, Y.-Z., Copps, J., Newby, M. L., He, L., Chavez, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37742-z · Cited by 56
Self-citationCD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies
Madani, N., Princiotto, A. M., Schön, A., LaLonde, J. M., Feng, Y., Freire, E., Park, J., Courter, J. R., Jones, D. M., Robinson, J. E., et al. (2014) · Journal of Virology · doi:10.1128/jvi.00540-14 · Cited by 53
Self-citationDepetris, R. S., Julien, J.-P., Khayat, R., Lee, J. H., Pejchal, R., Katpally, U., Cocco, N., Kachare, M., Massi, E., David, K. B., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.371898 · Cited by 51
Self-citationAsymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies
Wang, H., Gristick, H. B., Scharf, L., West, A. P., Galimidi, R. P., Seaman, M. S., Freund, N. T., Nussenzweig, M. C., & Björkman, P. J. (2017) · eLife · doi:10.7554/elife.27389 · Cited by 51
“Since the CDRH3 of unliganded PG9 Fab (PDB 3U36) is disordered, we modeled the unliganded PG9 coordinates and the ordered CDRH3 from the PG9 Fab in the PG9-V1V2 scaffold structure (PDB 3U4E) (McLellan et al., 2011) separately into the EM density.”
BackgroundMethodInfluentialWang, W., Li, Q., Wu, J., Hu, Y., Wu, G., Yu, C., Xu, K., Liu, X., Wang, Q., Huang, W., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1957720 · Cited by 55
Self-citationInfluence of glycosylation on the immunogenicity and antigenicity of viral immunogens
Newby, M. L., Allen, J. D., & Crispin, M. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108283 · Cited by 61
Usami, Y., & Göttlinger, H. G. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.028 · Cited by 48
“The V1/V2 region comprises a single topological entity that folds as four antiparallel b strands (McLellan et al., 2011).”
BackgroundInfluentialHIV-1 gp120 as a therapeutic target: navigating a moving labyrinth
Acharya, P., Lusvarghi, S., Bewley, C. A., & Kwong, P. D. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1010513 · Cited by 55
“1 Glycan-dependent antibodies A substantial proportion of recently identified, bNabs present in certain HIV-infected donors recognize glycan-dependent epitopes on HIV-1 gp120 (Figure 4) [39,78-80].”
BackgroundSelf-citationMechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies
Krumm, S. A., Mohammed, H., Le, K. M., Crispin, M., Wrin, T., Poignard, P., Burton, D. R., & Doores, K. J. (2016) · Retrovirology · doi:10.1186/s12977-016-0241-5 · Cited by 49
“A number of bnAb sites of vulnerability have been identified on HIV Envelope (Env) including the CD4 binding site, N-glycan-associated epitopes on the V1/ V2 loops (centred around N160) and the V3 loop (centred around N332) and regions on gp41 including the membrane proximal external region (MPER) and gp41 glycans [9–…”
BackgroundSelf-citationMengistu, M., Ray, K., Lewis, G. K., & DeVico, A. L. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004772 · Cited by 49
“In gp120, the most broadly reactive domains include the CD4 binding site [22–29], sequences encompassing a high mannose cluster (2G12 [30]) and glycosylated regions of V1V2 loop structures [31–38].”
BackgroundMurphy, M. K., Yue, L., Pan, R., Boliar, S., Sethi, A., Jianhui, T., Pfafferott, K. J., Karita, E., Allen, S. A., Cormier, E. G., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003173 · Cited by 53
“…VL, respectively), in terms of their structure, germline gene utilization, level of somatic hypermutation, and the features of their heavy chain third complementarity-determining regions (CDR H3s), has unveiled specific characteristics that facilitate extraordinary neutralizing capacity [8,12–15].”
BackgroundMayr, L. M., Cohen, S., Spurrier, B., Kong, X., & Zolla‐Pazner, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070859 · Cited by 47
Peachman, K. K., Karasavvas, N., Chenine, A.-L., McLinden, R., Rerks‐Ngarm, S., Jaranit, K., Nitayaphan, S., Pitisuttithum, P., Tovanabutra, S., Zolla‐Pazner, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143895 · Cited by 50
HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies
Sliepen, K., & Sanders, R. W. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1129905 · Cited by 51
“First, many bNAbs, in particular those directed to the V1V2 apex, contain very long heavy complementary determining region 3 (HCDR3) loops, which are very rare in the naïve B cell receptor repertoire.”
BackgroundInfluentialThe design and evaluation of HIV-1 vaccines
Saunders, K. O., Rudicell, R. S., & Nabel, G. J. (2012) · AIDS · doi:10.1097/qad.0b013e32835474d2 · Cited by 57
“both require an extended CDR H3 that recognizes a conserved glycan and nearby polypeptide [17,93].”
BackgroundSelf-citationGlycan modulation and sulfoengineering of anti–HIV-1 monoclonal antibody PG9 in plants
Loos, A., Gach, J. S., Hackl, T., Maresch, D., Henkel, T., Porodko, A., Minh, D. B., Sommeregger, W., Wozniak‐Knopp, G., Forthal, D. N., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509090112 · Cited by 52
“The crystal structure of PG9 in complex with its antigen has revealed that Y and Y of the PG9 heavy chain can be sulfated (4, 6).”
BackgroundMethodInfluentialHeterologous protein production using euchromatin-containing expression vectors in mammalian cells
Zboray, K., Sommeregger, W., Bogner, E., Gili, A., Sterovsky, T., Fauland, K., Grabner, B., Stiedl, P., Moll, H. P., Bauer, A., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv475 · Cited by 52
Sather, D. N., Carbonetti, S., Kehayia, J., Kraft, Z., Mikell, I., Scheid, J. F., Klein, F., & Stamatatos, L. (2012) · Journal of Virology · doi:10.1128/jvi.01893-12 · Cited by 58
“In addition, all clones were resistant to MAbs PG9 and PG16, which recognize a complex glycopeptide epitope at the base of the V2 loop (22), and to the anti-MPER MAb 2F5 (Table 3), although the canonical 2F5 epitope is present in all clones examined (see Fig.”
BackgroundWest, B. R., Moyer, C. L., King, L., Fusco, M. L., Milligan, J. C., Hui, S., & Saphire, E. O. (2018) · mBio · doi:10.1128/mbio.01674-18 · Cited by 47
The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template
Andrabi, R., Pallesen, J., Allen, J. D., Song, G., Zhang, J., de Val, N., Gegg, G., Porter, K., Su, C.-Y., Pauthner, M. G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.082 · Cited by 47
“This bnAb epitope sits at the 3-fold axis of the trimer and is primarily formed by a patch rich in positively charged lysine residues and protected by two glycans at HXB2 HIV reference positions N160 and N156/N173 that are part of the Env glycan shield (Andrabi et al., 2017; Bhiman et al., 2015; Bonsignori et al., 201…”
BackgroundMethodInfluentialSelf-citationMilligan, J. C., Davis, C. W., Yu, X., Ilinykh, P. A., Huang, K., Halfmann, P., Cross, R. W., Borisevich, V., Agans, K. N., Geisbert, J. B., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.023 · Cited by 49
“A single copy of PG9 binds the viral glycoprotein apex and contacts two gp120 protomers (McLellan et al., 2011).”
Voss, W. N., Mallory, M. L., Byrne, P. O., Marchioni, J., Knudson, S. A., Powers, J. M., Leist, S. R., Dadonaite, B., Townsend, D. R., Kain, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101668 · Cited by 53
“MS searches and MS data analyses were performed as previously described, 30 adjusting the stringency of the elution XIC:flowthrough XIC filter to 2:1.”
Self-citationUpadhyay, C., Mayr, L. M., Zhang, J., Kumar, R., Górny, M. K., Nadas, A. J., Zolla‐Pazner, S., & Hioe, C. E. (2014) · Journal of Virology · doi:10.1128/jvi.02125-14 · Cited by 47
“All N-glycans observed in the crystal structures of scaffolded V1V2 point away from the V2i (6, 16, 57).”
BackgroundBoyd, D. F., Peterson, D., Haggarty, B., Jordan, A. P. O., Hogan, M. J., Goo, L., Hoxie, J. A., & Overbaugh, J. M. (2014) · Journal of Virology · doi:10.1128/jvi.02680-14 · Cited by 44
“The epitopes of PG9 and PG16 depend on interactions involving neighboring gp120 subunits that come into contact in the envelope trimer (22, 25, 45).”
BackgroundLemmin, T., Soto, C. S., Stuckey, J., & Kwong, P. D. (2017) · Structure · doi:10.1016/j.str.2017.07.018 · Cited by 44
Self-citationHessell, A. J., Shapiro, M. B., Powell, R. L. R., Malherbe, D. C., McBurney, S. P., Pandey, S., Cheever, T., Sutton, W. F., Kahl, C., Park, B. S., et al. (2018) · Journal of Virology · doi:10.1128/jvi.02198-17 · Cited by 48
Kiss, G., Çelebi‐Ölçüm, N., Moretti, R., Baker, D. A., & Houk, K. N. (2013) · Angewandte Chemie · doi:10.1002/ange.201204077 · Cited by 44
Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design
Sadanand, S., Suscovich, T. J., & Alter, G. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-091014-090749 · Cited by 48
“However, recently it has become clear that even though glycans can mask critical sites of vulnerability, the shield itself is an immunogenic structure that is targeted by several bNAbs ranging from 2G12 to the more recently characterized potent PG and PGT antibody families (38, 58, 59).”
BackgroundStructural Dynamics of HIV-1 Envelope Gp120 Outer Domain with V3 Loop
Yokoyama, M., Naganawa, S., Yoshimura, K., Matsushita, S., & Sato, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037530 · Cited by 53
“Thus far fine structures of neither the intact gp120 monomer nor trimer are available. However, recent crystal structure study disclosed a structure of V1/V2 domain”
BackgroundChaipan, C., Pryszlak, A., Dean, H. J., Poignard, P., Beneš, V., Griffiths, A. D., & Merten, C. A. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.009 · Cited by 45
Unprecedented Role of Hybrid N- Glycans as Ligands for HIV-1 Broadly Neutralizing Antibodies
Shivatare, V. S., Shivatare, S. S., Lee, C.-C. D., Liang, C. J., Liao, K., Cheng, Y., Saidachary, G., Wu, C., Lin, N., Kwong, P. D., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b00896 · Cited by 45
Self-citationvan den Berg, F. T., Aminake, M. N., Ali, S. A., Scott, T. A., Mapengo, R. E., Mutsvunguma, L. Z., Mkhize, N. N., Lambson, B. E., Kgagudi, P., Crowther, C. E., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.002 · Cited by 47
“Antibodies targeting the V2 apex contain a characteristic heavy chain complementarity-determining region 3 (CDRH3) with an antigen-binding loop that is capable of penetrating the HIV-1 glycan shield.(15,16) The two most potent V2 bNAbs, PGDM1400 and CAP256-VRC26.”
BackgroundHessell, A. J., Powell, R. L. R., Jiang, X., Luo, C. C., Weiß, S., Dussupt, V., Itri, V., Fox, A., Shapiro, M. B., Pandey, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.074 · Cited by 41
“Structural data of PG9 and PG16 in complex with engineered V1V2 protein scaffolds or SOSIP have shown that V2q mAbs recognize a region in the C strand of V1V2 that assumes a β strand (rather than an α-helical) configuration and also bind to two N-linked glycans (McLellan et al., 2011; Pancera et al., 2013, 2014; Wang…”
BackgroundInfluentialConformational Heterogeneity of the HIV Envelope Glycan Shield
Yang, M., Huang, J., Simon, R., Wang, L., & MacKerell, A. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-04532-9 · Cited by 47
Self-citationUsing cross-species vaccination approaches to counter emerging infectious diseases
Warimwe, G. M., Francis, M. J., Bowden, T. A., Thumbi, S. M., & Charleston, B. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00567-2 · Cited by 55
Gombos, R. B., Kolodkin‐Gal, D., Eslamizar, L., Owuor, J. O., Mazzola, E., González, A., Korioth-Schmitz, B., Gelman, R. S., Montefiori, D. C., Haynes, B. F., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00783-15 · Cited by 44
“The symbol “ ” indicates pairs of antibodies that do not differ significantly. b PG9 10E8. c hu5A8 10E8 and 10E8 PG9, PGT126, VRC01, 4E10, and CH01. d hu5A8 PG9. e hu5A8 CH01. f 10E8 4E10. g PGT126 10E8, 4E10, and CH01. h PG9 4E10 and CH01. i PG9 PGT126.”
BackgroundInfluentialSelf-citationHepler, N. L., Scheffler, K., Weaver, S., Murrell, B., Richman, D. D., Burton, D. R., Poignard, P., Smith, D. M., & Pond, S. L. K. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003842 · Cited by 42
Self-citationBricault, C. A., Kovacs, J. M., Nkolola, J. P., Yusim, K., Giorgi, E. E., Shields, J. L., Perry, J., Lavine, C. L., Cheung, A., Ellingson-Strouss, K., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03331-14 · Cited by 46
“The quaternary structure of the acute, clade C gp140 trimers was assessed utilizing PGT145 IgG, which preferentially binds to intact trimers and targets variable loops 1 and 2 (V1/V2) and N-linked glycans in this region (24, 45).”
Method
Metadata
- Authors
- McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O’Dell, S., Patel, N., Shahzad-ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J. C., Chuang, G.-Y., Diwanji, D., Georgiev, I., Do Kwon, Y., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z.-Y., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Burton, D. R., Koff, W. C., Walker, L. M., Phogat, S., Wyatt, R., Orwenyo, J., Wang, L.-X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel, G. J., Schief, W. R., Ward, A. B., Wilson, I. A., & Kwong, P. D.
- Affiliations
- National Institutes of Health (US)
- University of Washington (US)
- Scripps Research Institute (US)
- Duke University (US)
- Tumaini University (TZ)
- International AIDS Vaccine Initiative (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Kwong, Peter D.
- ORCID
- McLellan, Jason S.
- Pancera, Marie
- Carrico, Chris
- Gorman, Jason
- Julien, Jean-Philippe
- Khayat, Reza
- Louder, Robert
- Patel, Nikita
- Yang, Yongping
- Zhang, Baoshan
- Zhou, Tongqing
- Zhu, Jiang
- Boyington, Jeffrey C.
- Chuang, Gwo-Yu
- Diwanji, Devan
- Georgiev, Ivelin
- Louder, Mark K.
- Moquin, Stephanie
- Schmidt, Stephen D.
- Bonsignori, Mattia
- Crump, John A.
- Kapiga, Saidi H.
- Haynes, Barton F.
- Burton, Dennis R.
- Koff, Wayne C.
- Walker, Laura M.
- Wyatt, Richard
- Wang, Lai-Xi
- Arthos, James
- Bewley, Carole A.
- Mascola, John R.
- Nabel, Gary J.
- Schief, William R.
- Ward, Andrew B.
- Wilson, Ian A.
- Kwong, Peter D.
- Venue
- Nature
- Published
- 2011-11-23
- Volume
- 480
- Issue
- 7377
- Pages
- 336-343
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3406929
- OpenAlex
- W2122617162
- Cited by
- 830
- References
- 69
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 23 · 2023: 25 · 2022: 36 · 2021: 38 · 2020: 39 · 2019: 52 · 2018: 63 · 2017: 70 · 2016: 64 · 2015: 84 · 2014: 92 · 2013: 120 · 2012: 78
- FWCI
- 36.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- U.S. Department of Energy (W - 31 - 109 - Eng - 38)
- International AIDS Vaccine Initiative
- Ragon Institute of MGH, MIT and Harvard
- National Institutes of Health
- Office of Science (W-31-109-ENG-38)
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI033292, R01AI084817)
- National Center for Research Resources (RR017573, P41RR017573)
- Basic Energy Sciences (W-31-109-Eng38)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- HIV-1 gp120, antibody-antigen complex structure, N-glycosylation, carbohydrate recognition, HIV vaccine development, envelope glycoprotein
- MeSH terms
- Amino Acid Sequence, Antibody Affinity, Antibody Specificity, Antigen-Antibody Complex, Epitopes, Binding Sites, Antibody, Glycopeptides, Glycosylation, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Polysaccharides, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, AIDS Vaccines, Conserved Sequence, Protein Structure, Tertiary, Crystallography, X-Ray, Amino Acid Motifs, Protein Structure, Quaternary, Immune Evasion, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.